IDHIFA (enasidenib) Patient Assistance Program
Don’t let the high cost of targeted leukemia therapy stand between you and the treatment you need. We help eligible patients access Idhifa (enasidenib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Idhifa (enasidenib) is FDA-approved for adults with relapsed or refractory acute myeloid leukemia (AML) who carry an IDH2 mutation as detected by an FDA-approved test.
- Without assistance, the list price is approximately $35,000 for a 30-tablet supply at the standard 100 mg daily dose, totaling roughly $420,000 per year if treatment continues continuously.
- Through AffordMyPrescriptions, qualifying patients can access Idhifa for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic version of Idhifa available in the U.S. as of 2026. Idhifa is dispensed only through a limited specialty pharmacy distribution network.
What is Idhifa Prescription Assistance Program?
The Idhifa Prescription Assistance Program is a manufacturer-sponsored initiative that provides Idhifa at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for uninsured and underinsured AML patients, as well as Medicare Part D beneficiaries who cannot afford targeted leukemia therapy.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, IDH2 mutation documentation, specialty pharmacy logistics, differentiation-syndrome monitoring, and renewal deadlines — all while managing relapsed or refractory AML.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through refill coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Idhifa costs approximately $35,000 per 30-tablet supply through the limited specialty pharmacy distribution network. Pharmacy discount coupons offer little relief at this price level. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Specialty Pharmacy (list) | ~$35,000.00 | Save ~$34,930/mo |
| Specialty Pharmacy (high) | ~$36,000.00 | Save ~$35,930/mo |
| Specialty Pharmacy (low) | ~$34,500.00 | Save ~$34,430/mo |
| Annual treatment cost | ~$420,000 | Save ~$419,000/yr |
| Manufacturer copay (insured) | $0/fill (cap $15K/yr) | Limited annual cap |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Idhifa Prescription Program?
The Patient Assistance Program is free to apply for and provides Idhifa at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, IDH2 mutation documentation, limited specialty pharmacy logistics, and ongoing renewal management — particularly important given the differentiation-syndrome monitoring required during early therapy. Our $69.95/month service covers full advocacy: applications, doctor coordination, documentation, refill management, and annual re-enrollment — so you focus on your treatment, not paperwork.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Idhifa:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
- Coupon cards expire and require constant renewal
- Still $34,500–$36,000 per month even with the best discount
- Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
- We manage all paperwork, refills, autoinjector coordination, and annual renewals
Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Idhifa assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Idhifa Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Idhifa:
Idhifa (enasidenib) is an oral, targeted oncology medicine used to treat adults with relapsed or refractory acute myeloid leukemia (AML) whose cancer carries a specific genetic change called an IDH2 mutation. It is taken as a daily tablet by mouth and is dispensed through a limited specialty pharmacy distribution network. Eligibility requires confirmation of IDH2 mutation status on an FDA-approved test before therapy is started.
How It Works:
Idhifa targets a specific mutation in the IDH2 gene that typically prevents blood cells from maturing, leading to a buildup of immature cells in the bone marrow. By inhibiting this mutant enzyme, the medication lowers abnormal molecules and allows these cells to resume their normal maturation process. Over time, this helps restore healthy blood cell production and reduces the overall leukemic burden.
Form and Use:
The standard treatment involves taking one 100 mg tablet by mouth once daily, which can be taken with or without food. Because the clinical response can develop slowly, patients usually continue the medication for at least six months unless the disease progresses or side effects become unacceptable. Long-term consistency is key to allowing the blood cells enough time to mature properly.
Generic Availability:
As of 2026, there is no FDA-approved generic version of Idhifa available in the U.S. due to ongoing patent and exclusivity protections. While other specialized treatments and inhibitors exist for different AML mutations, they are not direct substitutes for Idhifa. Decisions regarding alternative therapies or stem-cell transplants are made by the oncology team based on the patient’s specific mutation profile and health status.
Warnings:
Idhifa includes a boxed warning for differentiation syndrome, a serious condition that can occur as leukemia cells begin to mature into normal blood cells. Patients are advised to immediately report symptoms like fever, shortness of breath, or rapid weight gain to their medical team. Other potential risks include high white blood cell counts and embryo-fetal toxicity, requiring regular monitoring of blood counts and body chemistry.
FAQ (Frequently Asked Questions)
How Much Does Idhifa Cost Without Insurance?
The list price is approximately $35,000 per 30-tablet supply at the standard 100 mg daily dose. Idhifa is dispensed through a limited specialty pharmacy distribution network rather than at retail pharmacies, and pharmacy discount coupons leave a five-figure monthly bill even at their best. Through AffordMyPrescriptions, qualifying patients receive Idhifa at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is The IDH2 Mutation Confirmed?
The IDH2 mutation is confirmed through a molecular test on bone-marrow or blood samples, performed by a laboratory using an FDA-approved test. Idhifa is approved only for AML that has been confirmed IDH2-mutant on that kind of testing.
What Is Differentiation Syndrome And Why Does It Matter?
Differentiation syndrome is a clinical syndrome that can occur as IDH2-mutant blast cells start to mature into normal blood cells under treatment. Symptoms can include fever, shortness of breath, weight gain, swelling, low blood pressure, and kidney or liver dysfunction, and they can be serious. Idhifa carries a boxed warning for differentiation syndrome, and your oncology team will monitor for it, especially during the first months of therapy. Tell your team promptly about any new fevers, breathing changes, or rapid weight gain.
Are There Other AML Therapies I Should Know About?
Yes. AML treatment options can include non-targeted chemotherapy, the IDH1 inhibitor ivosidenib (for IDH1-mutant disease), the BCL-2 inhibitor venetoclax in combination regimens, FLT3 inhibitors for FLT3-mutant disease, and consideration of allogeneic stem-cell transplant in eligible patients. Whether any of these is a clinical fit for you depends on your specific mutation profile, prior therapy, age, and other factors. We mention this directly because if a different therapy on a more accessible assistance pathway would work for your situation, that may be a better path.
Can I Get Idhifa Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify for Idhifa Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay assistance program ($0 per 30-day supply, up to ~$15,000/year) is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What if my application is denied?
If your initial application is denied, we explore alternative savings paths on your behalf — including the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation or HealthWell Foundation, the Leukemia & Lymphoma Society for AML-specific support, or asking your oncology team whether a different AML regimen on a more accessible cost path would be appropriate. If we cannot find a path to medication access, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Idhifa, our team may be able to help you access assistance programs designed to make targeted leukemia therapy affordable. Check your eligibility today and take the first step toward predictable, sustainable treatment.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.